Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine for Post-Transplant Relapse in MDS, CMML, and AML
NCT01083706Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Apr 2010
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), acute myeloid leukemia (AML), sponsored by Fred Hutchinson Cancer Center. Started Apr 2010; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01083706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01083706.